据中国疾病预防控制中心公告显示,近期我国流感活动呈上升趋势。季节性流感的来袭,不仅考验着公共卫生防控体系的响应速度,也让医药产业链的保障能力成为关注焦点。从疫苗生产到药品供应,从传统制剂到创新药研发,国内药企正以多元举措构建起一道坚实的健康防护线。如华兰生物11月11日在互动平台回答投资者提问时表示,公司具备年产1亿剂流感疫苗的生产能力。截至目前,公司2025年共批签发流感疫苗54批,其中四价...
Source Link据中国疾病预防控制中心公告显示,近期我国流感活动呈上升趋势。季节性流感的来袭,不仅考验着公共卫生防控体系的响应速度,也让医药产业链的保障能力成为关注焦点。从疫苗生产到药品供应,从传统制剂到创新药研发,国内药企正以多元举措构建起一道坚实的健康防护线。如华兰生物11月11日在互动平台回答投资者提问时表示,公司具备年产1亿剂流感疫苗的生产能力。截至目前,公司2025年共批签发流感疫苗54批,其中四价...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.